Mc. Levesque et Bf. Haynes, TNF alpha and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44, CELL IMMUN, 193(2), 1999, pp. 209-218
Our previous studies have identified TNF alpha as a positive regulator and
IL-4 as a negative regulator of human monocyte CD44-HA binding. In order to
determine the mechanisms of IL-4- and TNF alpha-mediated regulation of mon
ocyte HA binding, we measured HA binding and CD44 expression on peripheral
blood monocytes following monocyte treatment with TNF alpha or IL-4, as wel
l as following monocyte treatment with inhibitors of protein synthesis, N-
and O-linked glycosylation, and chondroitin sulfation. IL-4 decreased CD44-
HA binding on monocytes initially treated with TNFa. Similarly, pretreatmen
t of monocytes with IL-4 prevented subsequent TNF alpha-mediated HA binding
. Cycloheximide (protein synthesis inhibitor), tunicamycin (N-linked glycos
ylation inhibitor), and beta-D-xyloside (chondroitin sulfation inhibitor) a
ll inhibited IL-4-mediated downregulation of TNF alpha-induced monocyte HA
binding. Western blot analysis of CD44 from TNF alpha-treated monocytes rev
ealed a 5-10 M-r decrease in the standard isoform of CD44. In contrast, IL-
4 treatment of monocytes inhibited CD44-HA binding and reversed the 5- to 1
0-kDa decrease in monocyte CD44 M-r. Finally, studies with F10.44.2, a CD44
mab that enhances CD44-HA binding, indicated that IL-4 treatment of monocy
tes not only diminished constitutive HA binding, but also diminished CD44 m
ab-induced HA binding. Taken together, these data suggested that IL-4-media
ted inhibition of TNF alpha-induced monocyte HA binding was dependent not o
nly on protein synthesis, but also on N-linked glycosylation and chondroiti
n-sulfate modification of either CD44 or, alternatively, another monocyte p
rotein(s) that may regulate the ability of CD44 to bind HA. (C) 1999 Academ
ic Press.